MERS Cov vaccine(Barinthus Biotherapeutics/University of Oxf

This MERS Cov vaccine(Barinthus Biotherapeutics/University of Oxford) Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 3 August 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether MERS Cov vaccine(Barinthus Biotherapeutics/University of Oxford) can convert its Recombinant vector vaccine, Prophylactic vaccine profile and MERS-CoV spike protein biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	MERS Cov vaccine(Barinthus Biotherapeutics/University of Oxford) (query alias: MERS Cov vaccine(Barinthus Biotherapeutics/University of Oxford))
Modality / target	Recombinant vector vaccine, Prophylactic vaccine; MERS-CoV spike protein; MERS-CoV spike protein inhibitors, Immunostimulants
Highest global status	Phase 2
Originator	Barinthus Biotherapeutics (UK) Ltd., University of Oxford
Active developers	Barinthus Biotherapeutics (UK) Ltd.

The MCP disease footprint includes Coronavirus Infections. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT04607850	Phase 1/2	Completed	108	Incidence of adverse events to measure safety and reactogenicity
NCT03399578	Phase 1	Terminated	29	Occurrence of solicited and unsolicited local and systemic adverse events
NCT04170829	Phase 1	Completed	24	Occurrence of solicited and unsolicited local and systemic adverse events

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial

Phase 1; n=24; evaluation: Positive. Reported fields: AE = mild 74%，moderate 19%

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

MERS Cov vaccine(Barinthus Biotherapeutics/University of Oxford) addresses Coronavirus Infections. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Recombinant vector vaccine, Prophylactic vaccine—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2023-12-21	New partnership between CEPI, Barinthus Biotherapeutics and the University of Oxford aims to advance vaccine against MERS coronavirus	Not disclosed	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO